Animal studies have shown that in the CLP sepsis model, sodium butyrate can significantly reduce lung injury and improve survival by inhibiting HDAC3, expanding Treg cells, and enhancing the gut-lung barrier (203); while in the antibiotic-induced gut microbiota dysbiosis mouse model, supplementing SCFAs can inhibit NLRP3/GSDMD-mediated pyroptosis and improve the prognosis of sepsis (204). This evidence concerns the gene GSDMD and Sepsis.